Organoidsciences KRX:476040KOSDAQ
오가노이드사이언스 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days1
DART filings, 7 days0
Articles tracked1since Sep 11
In Q2 2026, Organoidsciences reported revenue of ₩598m, down 1.1% year on year, and an operating loss of ₩4.4bn. Organoidsciences (오가노이드사이언스) appeared in 1 Korean news article and 0 DART filings over the past seven days. Coverage peaked on Sep 14 with 1 article. The most common catalyst was clinical & approvals (1).
Organoidsciences quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩598m | -1.1% | −₩4.4bn | −₩7.0bn |
| Q1 2026 | ₩144m | -43.6% | −₩4.2bn | −₩4.4bn |
| Q4 2025 derived | ₩1.2bn | -10.2% | −₩3.8bn | −₩3.6bn |
| Q3 2025 | ₩320m | +8.4% | −₩3.9bn | −₩3.9bn |
| Q2 2025 | ₩605m | +187.9% | −₩4.7bn | −₩4.5bn |
| Q1 2025 | ₩255m | – | −₩3.8bn | −₩3.7bn |
| Q4 2024 derived | ₩1.4bn | – | −₩2.1bn | −₩2.1bn |
| Q3 2024 | ₩295m | – | −₩3.4bn | −₩3.3bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.
Organoidsciences top stories 2 weeks, by number of outlets
- 1